{"id":"mepolizumab-250","safety":{"commonSideEffects":[{"rate":"10%","effect":"Injection site reaction"},{"rate":"10%","effect":"Headache"},{"rate":"5%","effect":"Nausea"},{"rate":"5%","effect":"Diarrhea"},{"rate":"5%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108429","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Mepolizumab is a recombinant humanized IgG1 monoclonal antibody that selectively binds to and neutralizes interleukin-5 (IL-5), a cytokine involved in the pathogenesis of asthma and eosinophilic granulomatosis with polyangiitis (EGPA).","oneSentence":"Interleukin-5 antagonist","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:00:26.932Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma"},{"name":"Eosinophilic granulomatosis with polyangiitis (EGPA)"}]},"trialDetails":[{"nctId":"NCT01000506","phase":"PHASE2","title":"Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-01","conditions":"Asthma","enrollment":621},{"nctId":"NCT01366521","phase":"PHASE2","title":"Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02","conditions":"Asthma","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Mepolizumab 250","genericName":"Mepolizumab 250","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"Interleukin-5 antagonist Used for Asthma, Eosinophilic granulomatosis with polyangiitis (EGPA).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}